Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud

WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections. But within weeks, investors were facing a much different picture—one that has now led to a securities class action lawsuit and an upcoming court deadline. Cohen Milstein Sellers & Toll PLLC, one of the nation’s top securities law firms, is calling on investors who purchased shares during the IPO to consider joining and seeking a ...